Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
Multiple myeloma (MM) is an incurable B-cell malignancy. Therefore, new targets and drugs are urgently needed to improve patient outcome. Epigenetic aberrations play a crucial role in development and progression in cancer, including MM. To target these aberrations, epigenetic modulating agents, such...
Main Authors: | Elke De Bruyne, Karin Vanderkerken, Ivan Van Riet, Ken Maes, Eline Menu, Els Van Valckenborgh |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/5/2/430 |
Similar Items
-
Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
by: Lien De Beck, et al.
Published: (2018-10-01) -
The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
by: Eva De Smedt, et al.
Published: (2018-12-01) -
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
by: Tandon N, et al.
Published: (2016-05-01) -
Implication des modifications épigénétiques dans les cancers : développement de nouvelles approches thérapeutiques
by: Willems L., et al.
Published: (2008-01-01) -
Epigenetic-Based Therapy—A Prospective Chance for Medulloblastoma Patients’ Recovery
by: Agata Strejczek, et al.
Published: (2021-05-01)